Gemcitabine chemotherapy-mediated immune mechanism of thrombocytopenia.docVIP

 PAGE \* MERGEFORMAT 7 Gemcitabine chemotherapy-mediated immune mechanism of thrombocytopenia Authors: Du, Xiao-Ping Qian, HU Wen-jing, LIU Bao-rui [Abstract] Objective To investigate the immune mechanism of gemcitabine chemotherapy-mediated thrombocytopenia treatment. Method of monitoring the gemcitabine chemotherapy in patients with thrombocytopenia platelet-associated antibodies in serum (PAIgG, PAIgM, PAIgA), antibody-positive with hormone therapy plus platelet antibodies returned to normal levels after the retest. The results of some of gemcitabine chemotherapy in patients with severe thrombocytopenia, in vivo anti-platelet antibodies produced, poor efficacy of conventional therapy, after treatment with hormone can increase blood as quickly returned to normal, anti-platelet antibodies was negative. Conclusion, after patients with gemcitabine chemotherapy, the body’s own immune response induced by anti-platelet antibodies produced, accelerated platelet destruction, this time with the hormone therapy and effective. [Keywords:] Gemcitabine; thrombocytopenia; immune response Gemzar (gemcitabine) are cell cycle specific anti-tumor drugs, research shows that the pairs of non-small cell lung cancer, pancreatic cancer, advanced breast cancer, ovarian cancer, bladder cancer, and so have a good effect [1]. We found that in clinical work, Gemzar on the impact of the patient’s blood system, mainly in areas of platelet inhibition, and sometimes the number of platelets can be as low as 20 * 109L-1 below, conventional use of growth promoting platelet-derived growth factor have been alleviated after the majority of patients , there are still a small number of patients with platelets continued to drop. The inspection found that some patients anti-platelet antibodies present in the blood. Our hospital in March 2004 and in October found two cases of patients by low-dose gemcitabine chemotherapy after a noticeable reduction of platelet and anti-platelet antibodies, af